Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

109,195 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial.
Xia Z, Leng Y, Fang B, Liang Y, Li W, Fu C, Yang L, Ke X, Jiang H, Weng J, Liu L, Zhao Y, Zhang X, Huang Z, Liu A, Shi Q, Gao Y, Chen X, Pan L, Cai Z, Wang Z, Wang Y, Fan Y, Hou M, Ma Y, Hu J, Liu J, Zhou J, Zhang X, Meng H, Lu X, Li F, Ren H, Huang B, Shao Z, Zhou H, Hu Y, Yang S, Zheng X, Wei P, Pang H, Yu W, Liu Y, Gao S, Yan L, Ma Y, Jing H, Du J, Ling W, Zhang J, Sui W, Wang F, Li X, Chen W. Xia Z, et al. Among authors: chen w, chen x. BMC Cancer. 2023 Oct 14;23(1):980. doi: 10.1186/s12885-023-11489-8. BMC Cancer. 2023. PMID: 37838670 Free PMC article. Clinical Trial.
[Overview of chronic myelogenous leukemia and its current diagnosis and treatment patterns in 15 hospitals in China.].
Wang JX, Huang XJ, Wu DP, Hu JD, Liu T, Hu Y, Meng FY, Chen XQ, Hou M, Li Y, Wang SJ, Wang JM, Ren HY, Yu L, Chen FY, Qiu LG, Jiang B, Sun AN, Liu TB, Zhu HL, Guo T, Xu D, Ji CY, Lü XY, Jiao L, Song XM, Huang HH. Wang JX, et al. Zhonghua Xue Ye Xue Za Zhi. 2009 Nov;30(11):721-5. Zhonghua Xue Ye Xue Za Zhi. 2009. PMID: 20137304 Review. Chinese.
Prognostic power of abnormal cytogenetics for multiple myeloma: a multicenter study in China.
Lai YY, Huang XJ, Cai Z, Cao XS, Chen FP, Chen XQ, Chen BA, Fang MY, Feng JF, Fu WL, Guo HY, Hou M, Hou J, Hu Y, Hu XT, Hu XM, Huang LQ, Jin J, Li JY, Li J, Li W, Liang YM, Liu T, Liu QF, Liu YH, Mao P, Ouyang J, Qiu LG, Qiu L, Shao CK, Shi B, Song YP, Sun ZM, Wang QS, Wang C, Wang JM, Wang YS, Wang Z, Wu JB, Wu YX, Xia RX, Xue YQ, Yang BZ, Yang G, Yang ZL, Yu L, Yuan Z, Zhang S, Zhang Y, Zhao HG, Zhao L, Zhou DB, Zou SH, Zhu YF. Lai YY, et al. Chin Med J (Engl). 2012 Aug;125(15):2663-70. Chin Med J (Engl). 2012. PMID: 22931972
Standardized fluorescence in situ hybridization testing based on an appropriate panel of probes more effectively identifies common cytogenetic abnormalities in myelodysplastic syndromes than conventional cytogenetic analysis: a multicenter prospective study of 2302 patients in China.
Lai YY, Huang XJ, Li J, Zou P, Xu ZF, Sun H, Shao ZH, Zhou DB, Chen FP, Liu ZG, Zhu HL, Wu DP, Wang C, Zhang Y, Li Y, Hou M, Du X, Wang X, Li W, Lai YR, Zhou J, Zhou YH, Fang MY, Qiu L, Wang XM, Zhang GS, Jiang M, Liang YM, Zhang LS, Chen XQ, Bai H, Lin JY. Lai YY, et al. Among authors: chen xq, chen fp. Leuk Res. 2015 May;39(5):530-5. doi: 10.1016/j.leukres.2015.02.005. Epub 2015 Feb 18. Leuk Res. 2015. PMID: 25823643
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China.
Shi Y, Jia B, Xu W, Li W, Liu T, Liu P, Zhao W, Zhang H, Sun X, Yang H, Zhang X, Jin J, Jin Z, Li Z, Qiu L, Dong M, Huang X, Luo Y, Wang X, Wang X, Wu J, Xu J, Yi P, Zhou J, He H, Liu L, Shen J, Tang X, Wang J, Yang J, Zeng Q, Zhang Z, Cai Z, Chen X, Ding K, Hou M, Huang H, Li X, Liang R, Liu Q, Song Y, Su H, Gao Y, Liu L, Luo J, Su L, Sun Z, Tan H, Wang H, Wang J, Wang S, Zhang H, Zhang X, Zhou D, Bai O, Wu G, Zhang L, Zhang Y. Shi Y, et al. Among authors: chen x. J Hematol Oncol. 2017 Mar 15;10(1):69. doi: 10.1186/s13045-017-0439-6. J Hematol Oncol. 2017. PMID: 28298231 Free PMC article.
Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study.
Hou J, Jin J, Xu Y, Wu D, Ke X, Zhou D, Lu J, Du X, Chen X, Li J, Liu J, Gupta N, Hanley MJ, Li H, Hua Z, Wang B, Zhang X, Wang H, van de Velde H, Richardson PG, Moreau P. Hou J, et al. Among authors: chen x. J Hematol Oncol. 2017 Jul 6;10(1):137. doi: 10.1186/s13045-017-0501-4. J Hematol Oncol. 2017. PMID: 28683766 Free PMC article. Clinical Trial.
Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 study.
Huang X, Qiu L, Jin J, Zhou D, Chen X, Hou M, Hu J, Hu Y, Ke X, Li J, Liang Y, Liu T, Lv Y, Ren H, Sun A, Wang J, Zhao C, Salman M, Sun S, Howes A, Wang J, Wu P, Li J. Huang X, et al. Among authors: chen x. Cancer Med. 2018 Apr;7(4):1043-1055. doi: 10.1002/cam4.1337. Epub 2018 Mar 13. Cancer Med. 2018. PMID: 29533000 Free PMC article. Clinical Trial.
109,195 results
You have reached the last available page of results. Please see the User Guide for more information.